Key takeaways
- PT-141 (bremelanotide) is a melanocortin receptor agonist that acts centrally on the nervous system rather than on blood flow, which sets it apart from vascular-acting compounds.
- In two randomized Phase 3 trials (the RECONNECT program), it improved sexual desire and reduced the distress tied to low desire compared with placebo in premenopausal women.
- It is approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, and it is being studied for further uses, including a recent obesity trial pairing it with tirzepatide.
- The benefit reported in HSDD trials is real but modest on average and varies from person to person, so eligibility and safety are best worked out with a physician.
- SCR is an education and coordination service; any treatment is delivered by licensed physicians at Innovita Clinic.
What PT-141 Is
PT-141, known by its approved name bremelanotide, treats low sexual desire by acting on the brain rather than on blood flow. It is a synthetic melanocortin receptor agonist, a structural analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring signaling peptide. Developed and studied specifically for sexual dysfunction, it was approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is given as a self-administered subcutaneous injection on an as-needed basis.
The approved use describes a specific clinical picture: acquired, generalized low sexual desire that causes marked distress and is not better explained by another medical condition, a relationship issue, or a medication. Identifying that picture correctly is itself a clinical judgment, which is one reason the compound is handled as a prescription product with physician involvement. That is the population the Phase 3 trials studied, and it is the use the research most directly supports.
How It Works
What sets PT-141 apart is where it acts. Unlike erectile-function drugs such as sildenafil that work on blood flow, PT-141 acts on melanocortin receptors in the central nervous system. According to the FDA prescribing information, bremelanotide nonselectively activates several melanocortin receptor subtypes, with binding to the MC1R and MC4R receptors being most relevant at therapeutic doses. The MC4 receptor is thought to be important for the brain pathways involved in sexual desire and arousal.
Early work published in 2003 established this central, non-vascular mechanism. In animal models, systemic PT-141 activated neurons in the hypothalamus and produced erectile responses, and early human dosing produced dose-dependent effects, pointing to a brain-level action rather than a direct vascular one. This is why the compound was studied around the experience of desire itself. A 2019 review later summarized this melanocortin mechanism alongside the efficacy and safety data, describing it as a genuinely different approach to a difficult clinical problem.
The Phase 3 Evidence
The strongest evidence for PT-141 comes from the RECONNECT program, two identical randomized Phase 3 trials published in 2019 (registered as NCT02333071 and NCT02338960). These were well-designed, double-blind, placebo-controlled studies that together randomized more than 1,200 premenopausal women with HSDD across sites in the United States and Canada. Compared with placebo, women taking bremelanotide showed statistically significant improvement in sexual desire and a significant reduction in the distress tied to low desire. The most common side effects were nausea, flushing, and headache, which the investigators described as mostly mild to moderate.
The size of that benefit deserves a clear-eyed read. The improvement over placebo was statistically significant, and at the same time the average effect in HSDD trials of this kind is modest and varies from person to person. The 2019 approval review documented this efficacy alongside the safety and tolerability data, which is part of why this is a prescription product.
Where the Science Is Heading Next
Researchers are extending the melanocortin approach beyond sexual desire. A Phase 2 trial completed in 2025 (NCT06565611) studied bremelanotide given alongside tirzepatide, an incretin medication used for weight management, to see whether adding the melanocortin pathway changes body weight, appetite, and body composition in adults with obesity. That study is early and its results will need to be reported and replicated before any conclusions can be drawn, but it shows where the science is actively looking next.
The evidence
Selected references, each verified against primary sources (PubMed, ClinicalTrials.gov, and the FDA label). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. PT-141 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.